|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.81 USD | +3.16% |
|
-0.65% | +12.22% |
| 08-04 | Ultragenyx Pharmaceutical Inc., Q2 2026 Earnings Call, Aug 04, 2026 | |
| 08-04 | Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q2 Loss of $0.90 per Share, vs. FactSet Est $1.22 Loss | MT |
| Market Cap | 2.53B 2.2B 2.05B 1.88B 3.56B 241B 3.6B 24.19B 9.46B 121B 9.52B 9.31B 399B | P/E 2026 * |
-5.72x | P/E 2027 * | -34.7x |
|---|---|---|---|---|---|
| Enterprise Value | 2.1B 1.82B 1.7B 1.56B 2.95B 200B 2.99B 20.04B 7.84B 99.86B 7.89B 7.71B 331B | EV / Sales 2026 * |
2.83x | EV / Sales 2027 * | 2.1x |
| Free-Float |
96.26% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ultragenyx Pharmaceutical Inc.
| 1 day | +3.16% | ||
| 1 week | -0.65% | ||
| Current month | +3.61% | ||
| 1 month | -22.89% | ||
| 3 months | +4.03% | ||
| 6 months | +4.54% | ||
| Current year | +12.22% |
| 1 week | 24.01 |  | 26.13 |
| 1 month | 24.01 | | 36.57 |
| Current year | 18.29 | | 36.57 |
| 1 year | 18.29 | | 39.89 |
| 3 years | 18.29 | | 60.37 |
| 5 years | 18.29 | | 104.38 |
| 10 years | 18.29 | | 179.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
CEO | Chief Executive Officer | 65 | 2010-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 49 | 2023-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | 53 | 2023-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
BRD | Director/Board Member | 65 | 2010-04-21 |
Matthew Fust
BRD | Director/Board Member | 61 | 2013-12-31 |
Michael Narachi
BRD | Director/Board Member | 66 | 2015-02-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/1/26 | Sell | Chief Financial Officer | -4,698 | 0.0048% | ||
| 5/14/26 | Free | Director | 21,809 | 0.0222% | ||
| 3/1/26 | Free | Executive/Senior Manager | 22,182 | 0.0230% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.16% | -0.65% | -9.31% | -31.48% | 2.53B | |
| +3.21% | +6.22% | -4.15% | -84.44% | 1.73B | |
| -1.09% | +2.61% | -12.91% | -20.84% | 321M | |
| +1.25% | +3.84% | -52.49% | - | 54.58M | |
| Average | +1.63% | +3.11% | -19.72% | -45.59% | 1.16B | |
| Weighted average by Cap. | +2.86% | +2.14% | -8.14% | -50.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 742M 644M 601M 552M 1.04B 70.57B 1.05B 7.08B 2.77B 35.28B 2.79B 2.72B 117B | 993M 863M 804M 739M 1.4B 94.5B 1.41B 9.48B 3.71B 47.24B 3.73B 3.65B 157B |
| Net income | -471M -409M -381M -350M -662M -44.77B -669M -4.49B -1.76B -22.38B -1.77B -1.73B -74.15B | -82.91M -71.99M -67.12M -61.66M -117M -7.89B -118M -791M -309M -3.94B -311M -305M -13.06B |
| Net Debt | -434M -377M -352M -323M -611M -41.3B -617M -4.14B -1.62B -20.65B -1.63B -1.59B -68.41B | -447M -389M -362M -333M -629M -42.57B -636M -4.27B -1.67B -21.28B -1.68B -1.64B -70.5B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-04 | US$25.81 | +3.16% | 2,103,772 |
| 26-08-03 | US$25.02 | +0.44% | 2,085,743 |
| 26-07-31 | US$24.91 | -4.34% | 1,537,765 |
| 26-07-30 | US$26.04 | +4.16% | 2,675,794 |
| 26-07-29 | US$25.00 | -3.77% | 2,330,792 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RARE Stock
Select your edition
All financial news and data tailored to specific country editions
